Piper Sandler Companies is an American multinational investment bank and financial services company, focused on mergers and acquisitions, financial restructuring, public offerings, public finance, institutional brokerage, investment management, and securities research.
Kardium secures **$250 million (CA$340 million)** in financing to commercially launch its **Globe® System**, a treatment for atrial fibrillation. The funds will also expand manufacturing capacity to support broader adoption of the technology. The company targets scaling production to meet anticipated demand for its non-invasive cardiac intervention solution.
OrganOx secures funding from **Intuitive Ventures** and **Terumo Ventures** in its second private placement round. The investors bring specialized **operating and clinical experience** to support OrganOx’s development. The company focuses on **medical technology innovations**, leveraging its expertise in organ preservation and transplantation solutions.
Saluda Medical secures **$100 million** in funding to advance its closed-loop neuromodulation platform. The round includes **Redmile Group** as lead investor, alongside returning backers like **Wellington Management** and **TPG Life Sciences Innovation**, as well as new participant **Piper Heartland Healthcare Capital**. Existing investors **Fidelity Management & Research**, **Action Potential Venture Capital**, and **T. Rowe Price Associates** also contribute to the financing.
Alentis Therapeutics secures **$181.4 million in Series D funding** from leading biotech investors to accelerate clinical development of **Anti-Claudin-1 antibody-drug conjugates (ADCs)** for treating **solid tumors**. The company targets **Claudin-1 positive (CLDN1+) tumors** and organ fibrosis, expanding its pipeline of targeted therapies.
Foley & Lardner advises Piper Sandler on the final closing of its **Piper Heartland Healthcare Crossover Fund I**, securing over **$200 million** in committed capital. The fund has already deployed **$40 million** across seven investments in the healthcare sector.
Piper Sandler Companies completes the final closing of its **Piper Heartland Healthcare Crossover Fund I**, securing over **$200 million in committed capital**. The fund targets investments in healthcare-related assets, bridging gaps between private equity and middle-market opportunities. The closing marks the fund’s full deployment readiness.
Piper Sandler closes its **Piper Heartland Healthcare Crossover Fund I** with over **$200 million** in committed capital. The fund has already deployed approximately **$40 million** across seven investments. Piper Sandler is a leading investment bank specializing in healthcare financing.
Piper Heartland Healthcare Capital
Heartland Healthcare Capital is Piper Sandler's healthcare investment platform; its crossover fund invests primarily in biotech, med-tech and healthcare information.